RxDoctor Payments Data

Barry Milder, MD

Ophthalmology · Saint Louis, MONPI 1659453637

Payments from drug & device makers

$622in general payments, 2019–2025

Across 15 payments — averaging $41.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$248
  • Bausch & Lomb Americas Inc.$125
  • Mallinckrodt Hospital Products Inc.$123
  • Johnson & Johnson Surgical Vision, Inc.$35
  • Oyster Point Pharma, Inc.$34
  • Sun Pharmaceutical Industries Inc.$18
  • plus $40 from 3 others

What the payments were for

  • Food & beverage$622100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$622 in reported general payments places this provider in the 35th percentile of 286 ophthalmology providers in Missouri.

See all ophthalmology providers in Missouri

Medicare billing

Part B allowed, 2024
$153,892
Medicare patients
774
Services billed
1,559

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost233$111,316
RestasisCyclosporine32$23,035
Alphagan PBrimonidine Tartrate54$14,034
RocklatanNetarsudil Mesylat/Latanoprost29$13,717
Cyclosporine18$8,572
RhopressaNetarsudil Mesylate21$7,066
Travoprost47$5,261
SimbrinzaBrinzolamide/Brimonidine Tart20$4,320
Latanoprost402$4,118
CombiganBrimonidine Tartrate/Timolol11$3,730
Brimonidine Tartrate77$3,241
Bimatoprost22$2,909
Brinzolamide18$2,733
Prednisolone Acetate88$2,557
Timolol Maleate20$2,397

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Alphagan P, Combigan$248$152,115330 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 286 ophthalmology providers in Missouri.

Other ophthalmology in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →